查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529664

血浆蛋白酶 C1 抑制剂市场规模、份额和趋势分析报告：按药物类别、剂型、分销管道、地区和细分市场预测，2024-2030 年

Plasma Protease C1-inhibitor Market Size, Share & Trends Analysis Report By Drug Class (C1-inhibitors, Kallikrein Inhibitor), By Dosage Form (Lyphophlised, Injectables), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

血浆蛋白酶 C1 抑制剂市场成长与趋势：

根据Grand View Research, Inc. Masu的最新报告，预计2030年全球血浆蛋白酶C1抑制剂市场规模将达到62.1亿美元，2024年至2030年复合年增长率为9.79%。

血浆蛋白酶 C1 抑制剂的全球市场是由遗传性血管水肿 (HAE)（一种罕见的遗传疾病）发病率上升以及对 C1 抑制剂等有效治疗方法的需求不断增长所推动的。此外，生物技术的进步提高了生产效率，并使这些疗法更容易获得。

对 HAE 及相关疾病的认识提高和诊断改进进一步促进了市场的显着增长。 HAE 影响着全世界约五万分之一的人，这凸显了迫切需要治疗方法来缓解症状并改善患者的生活品质。此外，生物技术的进步促进了基因工程产品的开发，为世界各地的患者带来了更大的功效和可及性。这些驱动因素对于塑造 C1-INH 产业格局、推动新治疗方案的采用和增加投资至关重要。

治疗技术的创新将重新定义各种病症的治疗标准。例如，采用长效製剂可延长治疗效果、减少治疗频率、提高患者遵从性。此外，正在进行的针对 HAE 以外的新兴适应症（例如抗体介导的自体免疫疾病）的研究表明，治疗方法在解决未满足的医疗需求方面具有多功能性和潜力。这些进步突显了该行业的动态本质，这是由旨在扩大治疗应用和优化患者治疗结果的持续研发努力所推动的。

随着产业不断扩张，市场相关人员越来越注重解决关键挑战和抓住成长机会。监管发展和有利的报销政策预计将进一步推动市场扩张，并使全球患者更容易获得 C1-INH 治疗。市场开拓公司正在利用这些监管发展来简化产业进入流程并确保及时获得创新治疗方法。 CSL Behring 和工业)等公司正在积极投资于产能扩张，以满足不断增长的需求并确保全球供应链的弹性。此外，我们与研究机构和监管机构的合作促进了创新并加快了新 C1-INH 治疗的核准流程。这些积极主动的倡议强调了我们对增加治疗选择和加强市场领导地位的承诺，并使我们的相关人员能够在不断发展的医疗保健领域实现持续成长和成功。

血浆蛋白酶 C1 抑制剂市场报告亮点

  • 从药物类别来看，C1抑制剂将在2023年占据市场主导地位并占据最大份额。由于主要企业实施研发倡议，选择性缓激肽 B2 受体拮抗剂预计在预测期内将以最快的成长率成长。
  • 从剂型来看，冷冻干燥製剂由于稳定性、保质期长、易于储存和运输而成为血浆蛋白酶 C1 抑制剂治疗的首选，将在 2023 年占据市场份额，从而增加对患者和医疗保健提供者的需求。保证双方的便利。
  • 从分销管道来看，2023年医院药局将占据市场主导地位。这是因为医院药局随处可见，符合法规，并且能够有效处理血浆蛋白酶 C1 抑制剂等专门疗法。
  • 由于高额医疗保健支出、先进的医疗保健基础设施、强大的研究以及针对遗传性血管性水肿等各种罕见疾病的血浆蛋白酶C1 抑製剂治疗的大量采用，北美在市场中占据主导地位，预计到2023 年将成为最大的市场。

目录

第一章调查方法和范围

第二章执行概述

第三章血浆蛋白酶 C1 抑制剂市场变数、趋势与范围

  • 血浆蛋白酶C1抑制剂市场系统展望
    • 母市场展望
    • 助剂市场前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 血浆蛋白酶 C1 抑制剂市场分析工具
    • 波特五力分析
    • PESTLE分析

第 4 章 2018-2030 年血浆蛋白酶 C1 抑制剂市场分析（按药物类别）（百万美元）

  • 2023 年和 2030 年按药物类别分類的市场占有率份额
  • 细分仪表板
  • 血浆蛋白酶 C1 抑制剂市场 – 依药物类别分類的前景
    • C1抑制剂
    • 激肽释放酶抑制剂
    • 选择性缓激肽 B2 受体拮抗剂

第 5 章 2018-2030 年血浆蛋白酶 C1 抑制剂市场分析（以剂型）（百万美元）

  • 2023 年和 2030 年按剂型分類的市场占有率份额
  • 细分仪表板
  • 血浆蛋白酶 C1 抑制剂市场 – 以剂型分類的展望
    • 冷冻干燥
    • 注射

第 6 章 2018-2030 年血浆蛋白酶 C1 抑制剂市场分析（按分销管道）（百万美元）

  • 2023 年和 2030 年按分销管道分類的市场占有率份额
  • 细分仪表板
  • 血浆蛋白酶 C1 抑制剂市场 – 按分销管道分類的展望
    • 医院药房
    • 零售药房
    • 网路药房

第 7 章血浆蛋白酶 C1 抑制剂市场：按药物类别分類的区域估计和趋势分析

  • 血浆蛋白酶 C1 抑制剂市场：区域展望
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第八章 竞争格局

  • 市场参与企业分类
  • 主要企业简介
    • CSL
    • Takeda Pharmaceutical Company Limited
    • Pharming
    • KalVista Pharmaceuticals.
    • Sanquin
    • BioCryst Pharmaceuticals, Inc.
    • CENTOGENE NV
Product Code: GVR-4-68040-328-1

Plasma Protease C1-inhibitor Market Growth & Trends:

The global plasma protease C1-inhibitor market size is anticipated to reach USD 6.21 billion by 2030, expanding at a CAGR of 9.79% from 2024 to 2030, according to a new report by Grand View Research, Inc. The global market for plasma protease C1-inhibitor is propelled by multiple pivotal factors such as the rising incidence of hereditary angioedema (HAE), a rare genetic disorder, increases the demand for effective therapies such as C1-inhibitor. Furthermore, advancements in biotechnology improve production efficiency, making these therapies more accessible.

Increased awareness and improved diagnosis of HAE and related conditions further contribute to substantial market growth. HAE affects approximately 1 in 50,000 individuals worldwide, underscoring the urgent need for therapies to alleviate symptoms and improve patient quality of life. Furthermore, advancements in biotechnology have enabled the development of recombinant products, which promise enhanced efficacy and accessibility for patients globally. These drivers are pivotal in shaping the landscape of the C1-INH industry, facilitating greater adoption and investment in novel treatment options.

Innovations in therapies are set to redefine treatment standards across various conditions. For instance, the introduction of long-acting formulations offers extended therapeutic effects, reducing treatment frequency and improving patient compliance. Additionally, ongoing research into new indications beyond HAE, such as antibody-mediated autoimmune diseases, showcases the versatility and potential of therapies in addressing unmet medical needs. These advancements underscore the dynamic nature of the industry, driven by continuous research and development efforts aimed at expanding therapeutic applications and optimizing patient outcomes.

Industry continues to expand; market players are increasingly focused on addressing key challenges and seizing opportunities for growth. Regulatory advancements and favorable reimbursement policies are anticipated to further propel market expansion, facilitating greater accessibility to C1-INH therapies for patients globally. Market players are leveraging these regulatory developments to streamline industry entry processes and ensure timely access to innovative treatments. Companies such as CSL Behring and Takeda Pharmaceutical are actively investing in expanding production capacities to meet escalating demand and ensure global supply chain resilience. Moreover, partnerships with research institutions and regulatory bodies are fostering innovation and accelerating the approval process for new C1-INH therapies. These proactive measures underscore a commitment to advancing treatment options and reinforcing market leadership, positioning stakeholders for sustained growth and success in the evolving healthcare landscape.

Plasma Protease C1-inhibitor Market Report Highlights:

  • Based on drug class, C1-inhibitors dominated the market and accounted for the largest share in 2023. Selective bradykinin B2 receptor antagonist anticipated to grow at the fastest growth rate over the forecast period owing to undergoing R&D initiatives being undertaken by major players
  • Based on dosage form, the lyophilized segment held a dominant share in 2023 due to their stability, longer shelf life, and ease of storage and transportation, making them preferred for plasma protease C1-inhibitor therapies, ensuring efficacy and convenience for patients and healthcare providers alike
  • Based on distribution channel, hospital pharmacies dominated the market in 2023 due to their widespread accessibility, regulatory compliance, and ability to handle specialized therapies like plasma protease C1-inhibitor effectively
  • North America dominated the market and accounted for the largest share in 2023 owing to high healthcare spending, advanced healthcare infrastructure, robust research, and significant adoption of Plasma Protease C1-inhibitor therapies for various rare diseases like hereditary angioedema.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Dosage form
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Drug Class and Dosage Form Snapshot
  • 2.3. Distribution Channel Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Plasma Protease C1-inhibitor Market Variables, Trends, and Scope

  • 3.1. Plasma Protease C1-inhibitor Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Disease Awareness
      • 3.2.1.2. Advancements in Treatment Options
      • 3.2.1.3. Expansion of Indications
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Cost of Treatment
      • 3.2.2.2. Side Effects and Safety Concerns
      • 3.2.2.3. Regulatory Challenges
  • 3.3. Plasma Protease C1-inhibitor Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTLE Analysis

Chapter 4. Plasma Protease C1-inhibitor Market Analysis, by Drug Class, 2018 - 2030 (USD Million)

  • 4.1. Drug Class Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Plasma Protease C1-inhibitor Market by Drug Class Outlook
    • 4.3.1. C1-inhibitors
      • 4.3.1.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.2. C1-esterase Inhibitor
      • 4.3.1.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.3. Recombinant Inhibitor
      • 4.3.1.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Kallikrein Inhibitor
      • 4.3.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Selective Bradykinin B2 Receptor Antagonist
      • 4.3.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Plasma Protease C1-inhibitor Market Analysis, by Dosage Form, 2018 - 2030 (USD Million)

  • 5.1. Dosage Form Market share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Plasma Protease C1-inhibitor Market by Dosage Form Outlook
    • 5.3.1. Lyphophlised
      • 5.3.1.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. Injectables
      • 5.3.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Plasma Protease C1-inhibitor Market Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

  • 6.1. Distribution Channel Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Plasma Protease C1-inhibitor Market by Distribution Channel Outlook
    • 6.3.1. Hospital Pharmacies
      • 6.3.1.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. Retail Pharmacies
      • 6.3.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Online Pharmacies
      • 6.3.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Plasma Protease C1-inhibitor Market: Regional Estimates and Trend Analysis by Drug Class, by Dosage Form

  • 7.1. Plasma Protease C1-inhibitor Market: Regional Outlook
  • 7.2. North America
    • 7.2.1. North America Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. U.S. Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.2.2.3. Competitive/Market Scenario
      • 7.2.2.4. Regulatory Framework
      • 7.2.2.5. Reimbursement scenario
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Canada Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.2.3.3. Competitive/Market Scenario
      • 7.2.3.4. Regulatory Framework
      • 7.2.3.5. Reimbursement Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Key Country Dynamics
      • 7.2.4.2. Mexico Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.2.4.3. Competitive/Market Scenario
      • 7.2.4.4. Regulatory Framework
      • 7.2.4.5. Reimbursement Scenario
  • 7.3. Europe
    • 7.3.1. Europe Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. UK Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.3. Competitive/Market Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. Reimbursement Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Germany Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.3.3. Competitive/Market Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Reimbursement Scenario
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. France Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.4.3. Competitive/Market Scenario
      • 7.3.4.4. Regulatory Framework
      • 7.3.4.5. Reimbursement Scenario
    • 7.3.5. Spain
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Spain Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.5.3. Competitive/Market Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Reimbursement Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Italy Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.6.3. Competitive/Market Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Reimbursement Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Denmark Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.7.3. Competitive/Market Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Reimbursement Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Sweden Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.8.3. Competitive/Market Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Reimbursement Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Norway Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.9.3. Competitive/Market Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Reimbursement Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Plasma Protease C1-inhibitor Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Japan Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.2.3. Competitive/Market Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Reimbursement Scenario
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. China Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.3.3. Competitive/Market Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. Reimbursement Scenario
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. India Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.4.3. Competitive/Market Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. Reimbursement Scenario
    • 7.4.5. Australia
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Australia Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.5.3. Competitive/Market Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Reimbursement Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Thailand Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.6.3. Competitive/Market Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Reimbursement Scenario
    • 7.4.7. South Korea
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. South Korea Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.7.3. Competitive/Market Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. Reimbursement Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Brazil Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.5.2.3. Competitive/Market Scenario
      • 7.5.2.4. Regulatory Framework
      • 7.5.2.5. Reimbursement Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Argentina Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.5.3.3. Competitive/Market Scenario
      • 7.5.3.4. Regulatory Framework
      • 7.5.3.5. Reimbursement Scenario
  • 7.6. MEA
    • 7.6.1. MEA Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. South Africa Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.6.2.3. Competitive/Market Scenario
      • 7.6.2.4. Regulatory Framework
      • 7.6.2.5. Reimbursement Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Saudi Arabia Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.6.3.3. Competitive/Market Scenario
      • 7.6.3.4. Regulatory Framework
      • 7.6.3.5. Reimbursement Scenario
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. UAE Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.6.4.3. Competitive/Market Scenario
      • 7.6.4.4. Regulatory Framework
      • 7.6.4.5. Reimbursement Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Kuwait Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.6.5.3. Competitive/Market Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Reimbursement Scenario

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Key Company Profiles
    • 8.2.1. CSL
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Takeda Pharmaceutical Company Limited
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Pharming
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. KalVista Pharmaceuticals.
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Sanquin
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. BioCryst Pharmaceuticals, Inc.
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. CENTOGENE N.V.
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global protease C1-inhibitor market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global plasma protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 Global plasma protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 6 Global plasma protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 North America protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 North America protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 10 North America protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 12 U.S. protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 13 U.S. protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14 Canada protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 15 Canada protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 16 Canada protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 18 Mexico protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 19 Mexico protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Europe protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Europe protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 23 Europe protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Germany protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Germany protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 26 Germany protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27 UK protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 28 UK protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 29 UK protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 France protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 31 France protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 32 France protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 Italy protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 Italy protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 35 Italy protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Spain protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 37 Spain protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 38 Spain protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 Denmark protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 Denmark protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 41 Denmark protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Sweden protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 43 Sweden protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 44 Sweden protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Norway protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 46 Norway protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 47 Norway protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 China protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 53 China protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 54 China protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55 Japan protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 56 Japan protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 57 Japan protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 India protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 59 India protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 60 India protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 South Korea protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 62 South Korea protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 63 South Korea protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64 Australia protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 65 Australia protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 66 Australia protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 Thailand protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 68 Thailand protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 69 Thailand protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 Latin America protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
  • Table 71 Latin America protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 72 Latin America protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 73 Latin America protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 Brazil protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 75 Brazil protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 76 Brazil protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77 Argentina protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 78 Argentina protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 79 Argentina protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80 MEA protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
  • Table 81 MEA protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 82 MEA protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 83 MEA protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84 South Africa protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 85 South Africa protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 86 South Africa protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 UAE protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 91 UAE protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 92 UAE protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93 Kuwait protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 94 Kuwait protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 95 Kuwait protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Plasma protease C1-inhibitor market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Drug class and dosage form segment snapshot
  • Fig. 11 Distribution channel segment snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Global Pharmaceutical Market, (USD billion)
  • Fig. 14 Market dynamics
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 PESTLE analysis
  • Fig. 17 Plasma protease C1-inhibitor: Drug Class outlook and key takeaways
  • Fig. 18 Plasma protease C1-inhibitor market: Drug Class market movement analysis
  • Fig. 19 C1-inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 C1-esterase Inhibitor market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Recombinant Inhibitor market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Kallikrein Inhibitor market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Selective Bradykinin B2 Receptor Antagonist market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Plasma protease C1-inhibitor: Dosage form outlook and key takeaways
  • Fig. 25 Plasma protease C1-inhibitor market: Dosage form market movement analysis
  • Fig. 26 Lyphophlised market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Injectables market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Plasma protease C1-inhibitor: Distribution channel outlook and key takeaways
  • Fig. 29 Plasma protease C1-inhibitor market Distribution channel market movement analysis
  • Fig. 30 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Retail Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Online Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Plasma protease C1-inhibitor market revenue, by region, 2023 & 2030 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Key country dynamics
  • Fig. 38 US plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 Canada plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 Mexico plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Europe plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 UK plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 Germany plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 France plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Spain plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Italy plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Denmark plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Sweden plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Norway plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Rest of Europe plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Japan plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 China plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 China regulatory details
  • Fig. 67 India plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Australia plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Thailand plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 South Korea plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 South Korea reimbursement scenario
  • Fig. 75 Rest of Asia Pacific plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Latin America plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Brazil plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Brazil regulation details
  • Fig. 80 Brazil reimbursement scenario
  • Fig. 81 Key country dynamics
  • Fig. 82 Argentina plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Argentina regulatory framework
  • Fig. 84 Rest of Latin America plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 South Africa plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Saudi Arabia plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 UAE plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 Kuwait plasma protease C1-inhibitor market estimates and forecasts, 2018
  • Fig. 93 Rest of MEA plasma protease C1-inhibitor market estimates and forecasts,
  • Fig. 94 Company/competition categorization
  • Fig. 95 Company market share analysis, 2023
  • Fig. 96 Strategy mapping